The importance of postapproval data for dabigatran

JAMA Internal Medicine

Volumn 175, Issue 1, 2015, Pages 25-

  Redberg, Rita F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

BLEEDING; DRUG APPROVAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICARE; RISK BENEFIT ANALYSIS; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; FEMALE; MALE;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HEMORRHAGE; HUMANS; MALE; WARFARIN;

EID: 84920573081     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.6265     Document Type: Editorial

References (2)

1. Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation [published online November 3, 2014]. JAMA Intern Med. doi:10. 1001/jamainternmed. 2014. 5398.
2. SouthworthMR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272-1274.